Metformin's labeled tablet strengths (500 mg, 850 mg, 1000 mg immediate-release; 500 mg, 750 mg, 1000 mg extended-release) and Riomet's single 100 mg/mL solution were set to cover the average adult titrating toward 2,000 mg/day. Those strengths were not chosen for a 6-year-old with new-onset type 2 diabetes who cannot swallow tablets and reacts to Riomet's cherry flavoring, for an adult with an eGFR of 35 who needs to sit on 250 mg twice daily for weeks before any uptitration, or for a patient whose dye allergy rules out every commercial tablet on the shelf. The molecule does the same thing in all of them. The dosage form and the excipient profile do not.
That gap is the narrow, legitimate work a compounding pharmacy does for metformin. A prescriber who knows the chart can order a dye-free, lactose-free, gluten-free capsule for a patient with documented excipient sensitivity, a flavored aqueous suspension in a vehicle that commercial Riomet does not offer, or a 125 mg or 250 mg capsule that no labeled tablet provides for slow renal-impaired titration. The molecule is the same metformin hydrochloride the FDA reviewed for Glucophage in 1994. The strength, the vehicle, and the excipient list are built around the patient in front of the prescriber, not the average trial participant.
This is what pharmacy looked like before mass manufacturing arrived. A doctor wrote the prescription. A pharmacist prepared it for that named patient. Compounded metformin is that older arrangement, kept honest by modern oversight and reserved for the cases where the manufactured product genuinely cannot meet the clinical need.
In brief
Compounded Metformin Explained
Metformin is the most widely prescribed oral medicine for type 2 diabetes. It lowers blood sugar mainly by reducing the amount of glucose the liver releases, with modest improvement in how the body's tissues respond to insulin. The FDA approved the brand-name tablet Glucophage in 1994. A liquid version, Riomet (100 mg/mL), is also FDA-approved for patients who cannot swallow tablets.
Because Glucophage, the extended-release versions, and Riomet liquid are already available, RonanRx does not compound metformin as a routine substitute for the manufactured products 27. Compounded metformin is reserved for specific clinical situations: a documented allergy to a tablet excipient, a liquid formulation in a flavor or vehicle that commercial Riomet does not provide, or a custom low-strength capsule that the labeled tablet strengths cannot deliver 2830.
At a glance
Quick Facts About Compounded Metformin
Category
Biguanide oral antihyperglycemic
Active ingredient
Metformin hydrochloride, a small-molecule biguanide derived from the guanidine-rich plant Galega officinalis, with an oral bioavailability of approximately 50, 60% and renal excretion of unchanged drug as the dominant elimination pathway
Oral, tablet, extended-release tablet, or oral solution
Evidence posture
Multi-decade randomized evidence supports the manufactured products for type 2 diabetes (UKPDS 34) and for delay of type 2 diabetes onset in adults at high risk (DPP/DPPOS); compounded preparations have no separate efficacy program
FDA-approval status
Manufactured Glucophage, Glumetza, Fortamet, and Riomet are FDA-approved. Compounded metformin is not FDA-approved.
Compounded under
503A, patient-specific prescription only, where the manufactured FDA-approved product is not clinically appropriate
Honest framing
Metformin is widely available as immediate-release and extended-release tablets and as Riomet 100 mg/mL oral solution. The 503A role is therefore narrow: liquid suspensions for pediatric or dysphagia patients whose needs are not met by commercial Riomet, allergen-free formulations for documented excipient sensitivity, alternate vehicles, and custom-strength capsules for renal-impaired patients titrated below commercial tablet increments. Compounding is not appropriate for cost-driven substitution.
Drug shortage context
Metformin has appeared on FDA's drug shortage list intermittently, most recently for specific extended-release presentations linked to nitrosamine impurity recalls in 2020. During an active shortage of a specific presentation, 503A compounding of that presentation may be permitted under section 503A(b)(1)(D); outside shortage, the essentially-a-copy restriction applies.
Prescription review
Patient-Specific Prescription Only
Compounded Metformin on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Compounded Metformin?
Metformin (1,1-dimethylbiguanide) is a small-molecule biguanide oral antihyperglycemic 31. It is descended from guanidine, the active hypoglycemic principle of Galega officinalis (French lilac, goat's rue), a plant used in medieval European medicine for polyuria and characterized chemically in the early twentieth century. Metformin itself was first synthesized by Werner and Bell in 1922 and re-developed for diabetes by Jean Sterne in the 1950s under the trade name Glucophage in France 21.
Metformin is marketed in the United States as Glucophage (immediate-release tablet, FDA-approved 1994), Glucophage XR / Glumetza / Fortamet (extended-release tablet formulations), and Riomet (oral solution 100 mg/mL, FDA-approved for patients unable to swallow tablets) 272831. Generic immediate-release and extended-release tablets are broadly available at all labeled strengths.
Compounded metformin is a pharmacy-prepared preparation dispensed under section 503A on a patient-specific prescription where the manufactured product cannot meet a documented clinical need 31. Compounded forms are typically a flavored oral suspension for pediatric or dysphagia patients whose needs commercial Riomet does not meet, an allergen-free or dye-free capsule for documented excipient sensitivity, or a custom low-strength capsule for renal-impaired patients titrated below the lowest commercial tablet.
How it works
How Compounded Metformin Works
Class
Biguanide
First studied
1922 synthesis; 1994 U.S. approval
Common forms
Capsule, custom excipient profile
Compounding category
503A, patient-specific prescription
Metformin lowers plasma glucose principally by suppressing hepatic gluconeogenesis. It is glucose-lowering without being insulin-secretagogue: it does not stimulate pancreatic insulin release and therefore does not produce hypoglycemia when used as monotherapy in non-fasted patients. Secondary mechanisms include modest improvement in peripheral (skeletal muscle and adipose) insulin sensitivity and a small decrease in intestinal glucose absorption.
At the molecular level, metformin produces mild inhibition of mitochondrial respiratory chain complex I, raising the cytosolic AMP:ATP ratio and activating AMP-activated protein kinase (AMPK). AMPK activation suppresses gluconeogenic gene expression and lipogenesis. More recently, Madiraju and colleagues 18 identified mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH) as a direct molecular target, and Foretz, Viollet and colleagues 19 integrated the redox and energy-charge models to explain how metformin suppresses gluconeogenesis from glycerol substrate independently of AMPK in some contexts. Rena, Hardie, and Pearson 33 reviewed the parallel molecular and integrative mechanisms of metformin action in 2017.
Effects on the gut microbiome are increasingly recognized as a mechanistic contributor. Wu and colleagues 17 demonstrated in treatment-naive adults with type 2 diabetes that metformin produces distinctive shifts in the gut microbiome and that microbiome-mediated changes in short-chain fatty acid production parallel its therapeutic glycemic effect.
Research history
Compounded Metformin Research History
Galega officinalis (French lilac) was used in medieval European herbal medicine for polyuria. Its guanidine and galegine content was identified as the active hypoglycemic principle in the early twentieth century, and metformin (1,1-dimethylbiguanide) was first synthesized by Werner and Bell in 1922. Jean Sterne re-developed metformin clinically in the 1950s in Paris and introduced it under the trade name Glucophage in 1959 for type 2 diabetes; the historical arc is reviewed by Bailey (2017) 2124. Metformin was approved by the FDA for type 2 diabetes in the United States in December 1994 (Glucophage).
The pivotal randomized evidence is UKPDS 34 1: 1,704 overweight adults with newly diagnosed type 2 diabetes were randomized to intensive control with metformin, intensive control with sulfonylurea or insulin, or conventional dietary treatment 23. Metformin reduced any diabetes-related endpoint by 32%, diabetes-related death by 42%, and all-cause mortality by 36% vs conventional treatment, with less weight gain and less hypoglycemia than sulfonylurea or insulin. The 10-year post-trial monitoring (UKPDS 80) 2 demonstrated persistence of macrovascular benefit despite convergence of glycemic control after the trial, the so-called legacy effect.
The Diabetes Prevention Program (DPP) 3 randomized 3,234 adults with impaired glucose tolerance to placebo, metformin 850 mg twice daily, or intensive lifestyle intervention. Over a mean of 2.8 years, lifestyle reduced incident type 2 diabetes by 58% and metformin by 31% relative to placebo. The Diabetes Prevention Program Outcomes Study (DPPOS) followed the cohort: at 10 years 4 the cumulative incidence of diabetes remained lower in the metformin and lifestyle arms; at 15 years the long-term weight-loss analysis 5 documented sustained mean 2.0% weight reduction among adherent metformin participants; and the 21-year long-term effects paper 6 reported continued separation in cumulative diabetes incidence with notable effect heterogeneity by baseline BMI and fasting glucose. Aroda and colleagues 13 additionally identified an increased prevalence of biochemical and clinical vitamin B12 deficiency in long-term metformin-treated participants, the most clinically actionable long-term safety signal of the cohort.
ADOPT 7 randomized 4,360 adults with newly diagnosed type 2 diabetes to rosiglitazone, metformin, or glyburide monotherapy. Cumulative incidence of monotherapy failure was lower with rosiglitazone (15%) than with metformin (21%) and glyburide (34%); however, the safety profile of rosiglitazone subsequently shifted prescribing back toward metformin as the first-line agent, a position cemented by Kahn 2006, UKPDS, and DPP and reflected in successive ADA Standards of Care.
Beyond diabetes, metformin has been studied in polycystic ovary syndrome 8910, gestational diabetes 11, cancer-incidence epidemiology 1516 (with confounding caveats), aging biology and geroscience, and altered gut microbiome composition 17. The TAME (Targeting Aging with Metformin) trial program 25 proposes metformin as a candidate intervention for biological aging endpoints; results have not yet been reported 26.
Timeline
Compounded Metformin Timeline
1922Werner and Bell synthesize 1,1-dimethylbiguanide (metformin) 21
1957Jean Sterne publishes the first clinical use of metformin for type 2 diabetes in Paris under the name Glucophage 21
1994FDA approves Glucophage (metformin hydrochloride) immediate-release tablet for type 2 diabetes in the United States (December 30, 1994) 27
1998UKPDS 34 (Lancet), metformin in overweight adults with newly diagnosed type 2 diabetes reduces any diabetes-related endpoint and all-cause mortality vs conventional dietary treatment 1
2002Diabetes Prevention Program (Knowler et al., NEJM), metformin reduces incident type 2 diabetes by 31% in adults with impaired glucose tolerance 3
2005Evans et al 15. (BMJ), observational signal of reduced cancer incidence among adults with type 2 diabetes treated with metformin
2006Kahn et al 7. (NEJM), ADOPT trial establishes glycemic durability of metformin monotherapy in newly diagnosed type 2 diabetes
2006Moll et al 8. (BMJ), clomifene plus metformin vs clomifene plus placebo for ovulation induction in newly diagnosed PCOS
2007Legro et al 9. (NEJM), clomiphene, metformin, or both for infertility in PCOS demonstrates clomiphene-superior live-birth rate
2008Holman et al 2. (NEJM), UKPDS 10-year post-trial monitoring (UKPDS 80) demonstrates persistent macrovascular benefit of metformin (legacy effect)
2008Rowan et al 11. (NEJM), MIG trial: metformin vs insulin for gestational diabetes, non-inferior on perinatal composite
2009Knowler et al 4. (Lancet), DPPOS 10-year follow-up confirms durable reduction in diabetes incidence with metformin and lifestyle
2009Currie et al 16. (Diabetologia), influence of glucose-lowering therapies on cancer risk in type 2 diabetes
2010Salpeter et al 12. (Cochrane), systematic review finds no excess fatal or nonfatal lactic acidosis with metformin use in type 2 diabetes
2011Graham et al 20. (Clin Pharmacokinet), comprehensive review of metformin clinical pharmacokinetics
2012Tang et al 10. (Cochrane), insulin-sensitising drugs (metformin and others) for PCOS-related oligo-amenorrhoea and subfertility
2014Bannister et al 14. (Diabetes Obes Metab), observational cohort comparing mortality of adults with type 2 diabetes on metformin or sulfonylurea monotherapy with matched non-diabetic controls
2014Madiraju et al 18. (Nature), metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
2014Foretz, Guigas, Bertrand, Pollak, Viollet (Cell Metab), review integrating redox- and energy-charge-based mechanisms of metformin's gluconeogenic suppression 19
2014Inzucchi et al 22. (JAMA), systematic review of metformin in patients with type 2 diabetes and kidney disease, supporting safer use at lower eGFR than the historical creatinine-based cut-off
2016FDA revises the metformin label to use eGFR instead of serum creatinine for renal contraindication thresholds (eGFR <30 mL/min/1.73 m² as the absolute contraindication; eGFR 30, 45 as caution) 27
2016Aroda et al 13. (J Clin Endocrinol Metab), long-term metformin use is associated with increased prevalence of biochemical and clinical vitamin B12 deficiency in DPPOS participants
2017Bailey (Diabetologia), historical overview of metformin from Galega officinalis to clinical use 21
2017Wu et al 17. (Nature Medicine), metformin alters the gut microbiome of treatment-naive adults with type 2 diabetes in a manner that contributes to its glycemic effect
2018Kulkarni et al 23. (Aging Cell), metformin regulates metabolic and non-metabolic pathways in skeletal muscle and adipose tissue of older adults
2018Justice et al 25. (Cardiovasc Endocrinol Metab), design and rationale for the TAME (Targeting Aging with Metformin) trial program
2019Aroda et al 5. (Ann Intern Med), long-term weight loss with metformin in DPPOS participants; sustained ~2% mean weight reduction at 15 years among adherent participants
2019Konopka et al 24. (Aging Cell), metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
2020FDA recalls multiple metformin extended-release products due to N-nitrosodimethylamine (NDMA) impurity exceeding the acceptable daily intake limit; specific presentations added to FDA drug shortage list 29
2022Justice et al 26. (Aging Cell), geroscience-guided repurposing of FDA-approved drugs to target aging, including the prioritization framework that places metformin among lead candidates
2025DPP/DPPOS long-term outcomes (Lancet Diabetes Endocrinol), 21-year cumulative diabetes incidence and effect heterogeneity of lifestyle and metformin interventions 6
Natural role
Biological Role of Compounded Metformin
Hepatic glucose production is the dominant determinant of fasting hyperglycemia in type 2 diabetes and a major contributor to post-prandial hyperglycemia. Excess gluconeogenesis is driven by hepatic insulin resistance, elevated counter-regulatory hormones, and increased availability of gluconeogenic substrates (glycerol, lactate, alanine). Metformin acts on this pathway directly, distinct from agents that augment insulin secretion (sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists) or that act on renal glucose reabsorption (SGLT2 inhibitors).
The biguanide class also has effects outside the glucose axis. Long-term observational and randomized data have explored signals for body-weight neutrality or modest weight loss 5, reduced incidence of microvascular and macrovascular complications 12, reduced cancer incidence in observational cohorts 1516 (with substantial methodologic caveats), and proposed effects on aging biology 2526. These extended biological roles motivate compound interest in metformin as a candidate geroscience agent and underlie the TAME (Targeting Aging with Metformin) trial program.
FDA-approved indication for manufactured metformin (Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet) and generics.
Metformin is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, alone or in combination with other antihyperglycemic agents and insulin. UKPDS 34 1 demonstrated in overweight adults with newly diagnosed type 2 diabetes that intensive control with metformin reduced any diabetes-related endpoint, diabetes-related death, and all-cause mortality compared with conventional dietary treatment. The 10-year post-trial monitoring (UKPDS 80) 2 showed persistent macrovascular benefit (legacy effect). ADOPT 7 established glycemic durability of metformin monotherapy in newly diagnosed type 2 diabetes 2728. Bannister and colleagues 14 reported in a large observational cohort that adults with type 2 diabetes initiated on metformin had lower mortality than matched non-diabetic controls, a hypothesis-generating finding that has motivated the geroscience research program around metformin 2526.
Type 2 diabetes mellitus in pediatric patients ages 10 years and older fda approved
FDA-approved indication for manufactured metformin immediate-release and oral solution (Riomet).
Metformin immediate-release tablets and Riomet oral solution (100 mg/mL) are FDA-approved for type 2 diabetes in pediatric patients ages 10 years and older 2827. The pediatric labeled indication is the primary clinical scenario where a liquid formulation is requested; commercial Riomet covers most needs. Compounded oral suspensions may be appropriate when commercial Riomet's flavor, excipient profile, or container closure cannot meet a documented patient-specific need.
Prevention or delay of type 2 diabetes in adults at high risk well studied
Off-label use supported by strong randomized evidence (DPP/DPPOS); endorsed by ADA Standards of Care but not an FDA-labeled indication.
The Diabetes Prevention Program 3 randomized 3,234 adults with impaired glucose tolerance to placebo, metformin 850 mg twice daily, or intensive lifestyle intervention. Over a mean 2.8 years, metformin reduced incident type 2 diabetes by 31% and lifestyle by 58% vs placebo. The DPPOS 10-year follow-up 4 confirmed durable risk reduction. The DPPOS long-term weight analysis 5 documented sustained ~2% mean weight reduction among adherent metformin participants at 15 years, and the 21-year long-term effects paper 6 reported continued separation in cumulative diabetes incidence. The use of metformin for diabetes prevention in adults with prediabetes is recommended by ADA Standards of Care but is not an FDA-labeled indication; it is off-label in the United States.
Polycystic ovary syndrome (PCOS), ovulation induction and metabolic features well studied
Off-label; supported by randomized evidence 8 and Cochrane review 10. Not an FDA-labeled indication.
Moll et al. 8 randomized 228 women with newly diagnosed PCOS to clomifene citrate plus metformin vs clomifene citrate plus placebo and found no significant difference in ovulation rate, with a non-significant trend toward more ovulation on the metformin arm. Legro et al. 9 subsequently randomized 626 infertile women with PCOS to clomiphene, metformin, or both for up to six months: live-birth rate was 22.5% with clomiphene alone, 7.2% with metformin alone, and 26.8% with combination, clomiphene was superior to metformin and not significantly improved by adding metformin. The Cochrane review by Tang and colleagues 10 integrated these and other trials. Metformin is appropriately positioned for PCOS as a metabolic adjunct rather than a first-line ovulation-induction agent.
Off-label; supported by the MIG randomized trial 11. Not an FDA-labeled indication; obstetric guideline positioning varies.
The Metformin in Gestational Diabetes (MIG) trial 11 randomized 751 women with gestational diabetes between 20 and 33 weeks of gestation to metformin (with supplemental insulin if required) or insulin alone. The primary composite perinatal outcome (neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar <7, or prematurity) occurred in 32.0% of the metformin group and 32.2% of the insulin group, non-inferiority. Maternal preference favored metformin. Long-term offspring follow-up of MIG and subsequent trials has been mixed; obstetric society positioning on metformin for GDM varies internationally and the indication is not FDA-labeled.
Aging biology and healthspan endpoints (TAME program) emerging
Investigational. The Targeting Aging with Metformin (TAME) trial program positions metformin as a candidate intervention for biological aging endpoints; results have not yet been reported. This is not an FDA-approved indication and remains an active research question.
Justice and colleagues 25 described the design and rationale for the TAME (Targeting Aging with Metformin) trial program, which positions metformin as a candidate intervention for composite aging endpoints (incident cardiovascular events, cancer, dementia, mortality) in adults aged 65, 79 without diabetes. The geroscience repurposing framework 26 places metformin among lead candidates on the basis of its safety profile, mechanism, and observational signals such as the Bannister cohort 14. The Konopka observation 24 that metformin attenuates mitochondrial adaptations to aerobic exercise training is a relevant caveat for healthspan-oriented use in older adults engaged in exercise interventions, and the Kulkarni skeletal-muscle and adipose study 23 characterizes the broader pathway regulation. No phase III aging-endpoint trial of metformin has yet reported.
Cancer incidence and mortality in adults with type 2 diabetes emerging
Hypothesis-generating observational signal only; randomized evidence does not support a clinical claim. Not an FDA-labeled indication.
Evans and colleagues 15 reported in a Tayside, Scotland record-linkage study a 23% reduction in incident cancer among adults with type 2 diabetes treated with metformin compared with non-metformin antihyperglycemic therapy. Currie and colleagues 16 extended this analysis in a UK General Practice Research Database cohort and found differential cancer-incidence signals across glucose-lowering therapies, including a directionally favorable signal for metformin vs insulin. Both studies are subject to immortal-time bias, time-related confounding, and indication-related confounding, and subsequent randomized analyses have not confirmed a cancer-prevention effect. The cancer-incidence literature is therefore positioned as hypothesis-generating, not actionable.
Off-label use
Off-Label Uses of Compounded Metformin
Prevention or delay of type 2 diabetes in adults at high risk well studied
Off-label in the U.S.; recommended by ADA Standards of Care on the basis of DPP/DPPOS.
Metformin 850 mg twice daily reduced incident type 2 diabetes by 31% over a mean 2.8 years in DPP 3; benefit persisted at 10 4, 15 5, and 21 6 years. ADA Standards of Care recommend metformin for diabetes prevention in selected adults with prediabetes; FDA labeling does not include this indication.
Off-label use is well documented in PCOS for ovulation adjunct, menstrual regularity, and metabolic features 8910; metformin is not a first-line ovulation-induction agent (clomiphene and letrozole are superior on live-birth endpoints).
MIG 11 randomized 751 women with GDM and reported non-inferiority of metformin vs insulin on a composite perinatal outcome; obstetric positioning varies internationally.
Aging biology and healthspan (TAME program) emerging
Investigational off-label.
Hypothesis-generating; TAME trial design 25 and geroscience prioritization 26 frame metformin as a candidate aging-intervention agent. No phase III aging-endpoint trial has yet reported.
FDA-approved use
FDA-Approved Uses of Compounded Metformin
Brand
Indication
Year
Route
Glucophage / Glucophage XR
Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ages 10 years and older with type 2 diabetes mellitus
1994
Oral (immediate-release and extended-release tablet)
Glumetza
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
2005
Oral (extended-release tablet)
Fortamet
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
2004
Oral (extended-release tablet)
Riomet
Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ages 10 years and older with type 2 diabetes mellitus
2003
Oral solution, 100 mg/mL
Metformin hydrochloride is FDA-approved in the United States as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ages 10 years and older with type 2 diabetes mellitus. Manufactured products include Glucophage (immediate-release tablet, December 1994), Glucophage XR / Glumetza / Fortamet (extended-release tablet formulations), and Riomet (oral solution, 100 mg/mL) 28. Multiple generic immediate-release and extended-release tablet products are available at standard strengths.
Metformin labeling carries a Boxed Warning regarding lactic acidosis, a rare but serious metabolic complication 28. The 2016 label revision changed the renal contraindication from serum-creatinine-based thresholds to estimated glomerular filtration rate (eGFR), with eGFR <30 mL/min/1.73 m² as the absolute contraindication and eGFR 30, 45 mL/min/1.73 m² as the caution zone where initiation is not recommended and continuation is at lower dose with closer monitoring 2722.
Compounded use
Compounded Compounded Metformin (503A)
Compounded metformin under 503A occupies a narrow and honest role. Metformin is widely available as immediate-release tablets (500, 850, 1000 mg), extended-release tablets (Glucophage XR, Glumetza, Fortamet, and generics), and as Riomet 100 mg/mL oral solution 2728. The commercial Riomet liquid covers most non-tablet clinical needs, including pediatric patients ages 10 and older 6. Compounding under section 503A is therefore appropriate only when a documented patient-specific clinical need cannot be met by the manufactured products, and routine compounding of essentially-a-copy preparations is not permitted 30312.
RonanRx limits 503A compounded metformin to four documented patient-specific scenarios: (1) liquid oral suspensions in flavor, vehicle, or excipient profiles that commercial Riomet cannot provide, typically for pediatric patients or adults with dysphagia or enteral-feeding access; (2) allergen-free or dye-free capsules for patients with documented sensitivity to a Glucophage / Glucophage XR / generic tablet excipient (e.g., povidone, polyethylene glycol, hypromellose, a colorant, or a lactose-containing filler); (3) alternate vehicle preparations for documented sensitivity to a commercial liquid excipient; and (4) custom low-strength capsules (e.g., 100 mg or 250 mg) for renal-impaired patients (eGFR 30, 45 mL/min/1.73 m²) titrated below the lowest commercial tablet strength on a prescriber-documented basis 272231.
The regulatory context for metformin compounding differs from the recent GLP-1 receptor agonist shortage situation. Metformin has appeared on FDA's drug shortage list only intermittently, most recently for specific extended-release presentations associated with NDMA nitrosamine impurity recalls in 2020 295. Outside an active shortage of a specific presentation, the essentially-a-copy restriction applies in full and compounding cannot be used as a price-driven substitute for the manufactured products 3031.
Compounded metformin preparations are not bioequivalent to the manufactured products 31. Clinicians and patients should understand that absorption, glycemic response, and tolerability of a compounded oral suspension or capsule may differ from published Glucophage, Glucophage XR, or Riomet data, particularly when excipients, concentration, vehicle, or container closure differ from the reference product 7. The published efficacy and safety evidence base for metformin is generated with manufactured product and does not transfer to compounded preparations without separate stability and patient-specific tolerability evaluation 134.
Formulations and routes
Compounded Metformin Formulations and Routes
Form
Concentration
Description
Compounded oral suspension
Custom, commonly 100 mg/mL matched to commercial Riomet, or alternate strength on prescriber order
Nonsterile oral liquid prepared under USP <795> standards in a flavored, dye-free, or excipient-free vehicle as documented by the prescriber's patient-specific clinical need. Beyond-use dating is assigned per pharmacy stability data.32
Custom, commonly 100, 250, 500, 750, or 1000 mg per capsule
Nonsterile capsule preparation under USP <795> for documented excipient sensitivity to a commercial tablet, or for custom low-strength titration below the lowest commercial tablet (500 mg IR; 500 mg or 750 mg XR).32
Riomet oral solution, FDA-approved 2003 for adults and pediatric patients ages 10 and older. Cherry-flavored, sugar-free.28
Routes used in published literature: oral.
Dosing
Compounded Metformin Dosing
Route
Population
Range
Duration
Study type
Oral
Adults with type 2 diabetes (immediate-release labeled regimen)
Start 500 mg twice daily with meals, or 850 mg once daily, and titrate in 500 mg weekly increments (or 850 mg every two weeks) to a maintenance dose of 2,000 mg/day. Maximum 2,550 mg/day in divided doses.
Indefinite while clinically beneficial and renal function is preserved
Adults with type 2 diabetes (extended-release labeled regimen)
Start 500 mg once daily with the evening meal; titrate in 500 mg weekly increments to a maintenance dose of 1,500, 2,000 mg/day. Maximum 2,000 mg/day (Glucophage XR) or 2,500 mg/day (Fortamet).
Indefinite while clinically beneficial and renal function is preserved
Pediatric patients ages 10, 16 years with type 2 diabetes
Start 500 mg twice daily with meals; titrate in 500 mg weekly increments to a maximum of 2,000 mg/day in divided doses. Extended-release formulations are not approved for pediatric use.
Indefinite while clinically beneficial and renal function is preserved
Adults with renal impairment (eGFR 30, 45 mL/min/1.73 m²)
Initiation not recommended; in patients already on metformin, reduce dose to ~half-maximum (typically 1,000 mg/day in divided doses) and monitor renal function more frequently. Contraindicated at eGFR <30.
Until eGFR falls below 30 mL/min/1.73 m² or until clinical contraindication develops
Doctor-prescribed and titrated. Metformin titration is paced to gastrointestinal tolerability, diarrhea, nausea, and abdominal discomfort are dose- and rate-dependent and are concentrated in the first weeks of therapy. Slow titration (500 mg per week) and administration with the largest meal are the primary tolerability levers; switching to extended-release reduces GI events in many patients.
Compounded metformin preparations should mirror the manufactured-product dosing intent unless the prescriber documents a patient-specific reason for variance 22. A custom low-strength capsule for an eGFR 30, 45 patient, for example, is appropriate when the patient cannot reliably split a 500 mg tablet and a commercial 250 mg presentation is unavailable; the prescribing intent should be documented in the chart and the pharmacy record 27.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Compounded Metformin Safety
Safety overview
Metformin's safety profile is favorable relative to most antihyperglycemic agents. The dominant adverse events are gastrointestinal: diarrhea, nausea, abdominal discomfort, and metallic taste, concentrated in the first weeks of therapy and dose-dependent. Across UKPDS 34 1, DPP 3, ADOPT 7, and clinical practice, metformin does not cause hypoglycemia as monotherapy and is associated with weight neutrality or modest weight loss 5. Hypoglycemia risk emerges when metformin is combined with insulin or insulin secretagogues 27.
Lactic acidosis carries a Boxed Warning in U.S. labeling on the basis of historical phenformin-era data and isolated case reports. The Cochrane systematic review by Salpeter and colleagues 12 pooled 347 prospective comparative trials and cohort studies (70,490 patient-years on metformin) and found no cases of fatal or nonfatal lactic acidosis attributable to metformin; the pooled upper confidence limit was 4.3 cases per 100,000 patient-years, indistinguishable from non-metformin therapy 27. Risk is concentrated in patients with acute or chronic renal impairment, decompensated heart failure, hepatic impairment, acute illness with reduced perfusion, or recent iodinated contrast exposure. The 2016 FDA label revision moved the renal threshold from creatinine to eGFR (absolute contraindication at eGFR <30, caution at 30, 45), informed by the Inzucchi systematic review 22.
Vitamin B12 deficiency is the most clinically actionable long-term safety signal. Aroda and colleagues 13 analyzed DPPOS participants on long-term metformin and reported increased prevalence of biochemical (serum B12 <298 pg/mL) and clinical B12 deficiency vs placebo, with the risk increasing with cumulative metformin exposure. Annual or biennial B12 monitoring is appropriate for patients on multi-year metformin therapy, particularly older adults and those with neuropathy 27.
Cardiovascular safety is supported by UKPDS 34 1 and the 10-year post-trial monitoring 2, and is reinforced by the REACH registry analysis by Roussel and colleagues 34, which reported lower 2-year all-cause mortality among adults with diabetes and established atherothrombosis treated with metformin. Pancreatitis, hepatotoxicity, and hypersensitivity are not characteristic of metformin. The Bannister observational cohort 14 reported that adults with type 2 diabetes initiated on metformin had lower all-cause mortality than matched non-diabetic controls, a hypothesis-generating signal that has driven the geroscience research program 2526 but does not on its own justify a healthspan claim 27. Compounded preparations may differ from manufactured products in absorption, tolerability, and excipient profile; safety data summarized here from manufactured products cannot be assumed to translate without modification to compounded preparations.
Contraindications
Metformin is contraindicated in: severe renal impairment (eGFR <30 mL/min/1.73 m²); acute or chronic metabolic acidosis, including diabetic ketoacidosis; and known hypersensitivity to metformin hydrochloride 27. Per the 2016 label revision, initiation of metformin is not recommended at eGFR 30, 45 mL/min/1.73 m²; patients already on metformin in this range may continue at a reduced dose with closer renal monitoring 2722.
Temporary discontinuation is recommended before iodinated contrast procedures in patients with eGFR 30, 60, in patients with a history of liver disease, alcoholism, or heart failure, or in any patient who will receive intra-arterial iodinated contrast; metformin should be withheld at the time of, or before, the procedure and restarted only after renal function has been re-evaluated and found stable. Metformin should be withheld during acute illness that may impair renal function (sepsis, dehydration, severe gastrointestinal illness).
Drug interactions
Metformin is not metabolized by cytochrome P450 enzymes and does not participate in CYP-mediated drug-drug interactions. The dominant pharmacokinetic interactions involve renal cation-transporter substrates: cimetidine, dolutegravir, ranolazine, vandetanib, trimethoprim, and isavuconazole can increase metformin plasma exposure by inhibiting renal tubular secretion through OCT2 / MATE1. Carbonic anhydrase inhibitors (topiramate, acetazolabide) increase the risk of metabolic acidosis when combined with metformin 2720.
Pharmacodynamic interactions include: increased risk of hypoglycemia when metformin is combined with insulin, sulfonylureas, or meglitinides (consider down-titration of the insulin-secretagogue or insulin dose); attenuation of glycemic effect with chronic corticosteroids, thiazide and loop diuretics, or sympathomimetics; and risk of lactic acidosis with concurrent ethanol misuse. Iodinated contrast: see contraindications section.
Adverse events
The most common adverse events are gastrointestinal: diarrhea, nausea, abdominal pain, flatulence, and metallic taste, concentrated in the first 2, 4 weeks of therapy and during dose escalation. In UKPDS 34, DPP, and ADOPT, GI adverse-event-driven discontinuation occurred in approximately 5, 10% of metformin-initiating participants 137. Hypoglycemia does not occur with metformin monotherapy 27. Weight is neutral to slightly favorable 5. Asthenia, headache, and rhinitis are reported at low incidence.
Serious adverse events are uncommon. Lactic acidosis is the most consequential reported event; the Cochrane review 12 found no cases attributable to metformin across 347 trials and 70,490 patient-years. Risk concentrates in patients with renal, hepatic, or cardiac failure or with acute illness. Vitamin B12 deficiency emerges with long-term exposure 13; clinical sequelae include macrocytic anemia and peripheral neuropathy that may be confounded with diabetic neuropathy. Hepatotoxicity, hematologic toxicity, and hypersensitivity are not characteristic of metformin 27. Pharmacovigilance signals from compounded preparations are formulation-specific and cannot be inferred from the manufactured-product evidence base.
Monitoring
Monitoring Compounded Metformin Therapy
Baseline assessment should include weight, blood pressure, HbA1c, fasting plasma glucose, hepatic transaminases, complete blood count, serum vitamin B12, and a comprehensive metabolic panel with calculated eGFR 22. Renal function should be reassessed at least annually, more frequently in older adults, in patients with eGFR <60, or in patients on concurrent renally cleared drugs.
On therapy: HbA1c every 3 months until at glycemic target and at least every 6 months thereafter; eGFR at least annually (more frequently as above); serum vitamin B12 every 1, 2 years for patients on multi-year metformin therapy, with measurement of methylmalonic acid or homocysteine in patients with low-normal B12 and neurologic symptoms 13. Hold metformin during acute illness that risks dehydration or hypotension and before iodinated contrast procedures per labeling 2722.
Special populations
Compounded Metformin in Special Populations
Pregnancy
Metformin crosses the placenta. The MIG randomized trial 11 compared metformin (with supplemental insulin if needed) vs insulin alone in 751 women with gestational diabetes and reported non-inferiority on a composite perinatal outcome. The use of metformin in gestational diabetes is off-label in the United States; obstetric society positioning varies internationally. For pregestational type 2 diabetes, U.S. guidance traditionally favors insulin during pregnancy, though metformin is sometimes continued in early pregnancy on a patient-specific basis. Long-term offspring follow-up data from MIG and subsequent trials have been mixed.
Lactation
Metformin is present in breast milk in low concentrations; published lactation data have not identified adverse effects on breastfed infants 27. Decision-making considers the developmental and health benefits of breastfeeding alongside the patient's clinical need and the infant's clinical status.
Pediatric
Metformin immediate-release tablets and Riomet oral solution are FDA-approved for type 2 diabetes in pediatric patients ages 10 years and older 2728. Extended-release tablet formulations are not approved for pediatric use. Compounded oral suspensions may be appropriate when commercial Riomet's flavor or excipient profile cannot meet a documented patient-specific need.
Geriatric
Older adults frequently have age-related reductions in renal function that lower the safe maximum metformin dose. Dose should be titrated against eGFR rather than serum creatinine alone 2227. The Konopka observation 24 that metformin attenuates mitochondrial adaptations to aerobic exercise training is a clinically relevant caveat for older adults engaged in exercise-based interventions. The Kulkarni skeletal-muscle and adipose study 23 characterizes broader pathway regulation in this population.
Renal impairment
Per the 2016 FDA label revision, metformin is contraindicated at eGFR <30 mL/min/1.73 m². Initiation is not recommended at eGFR 30, 45 mL/min/1.73 m². Patients already on metformin who fall into the eGFR 30, 45 range may continue at a reduced dose (typically up to 1,000 mg/day in divided doses) with more frequent renal monitoring 27. The Inzucchi systematic review 22 supports safer use of metformin at lower eGFR than the historical creatinine-based cut-off and informed the 2016 label revision. Custom low-strength compounded capsules (e.g., 100 or 250 mg) may be appropriate for patients in this band who cannot use a manufactured strength on a prescriber-documented basis.
Hepatic impairment
Hepatic impairment increases the risk of lactic acidosis through impaired lactate clearance. Metformin should be avoided in patients with clinical or laboratory evidence of hepatic disease, including chronic alcohol use disorder 27.
Evidence quality
Compounded Metformin Evidence Quality
Evidence supporting the manufactured metformin products is among the strongest in endocrinology 303418. UKPDS 34 1 and the 10-year post-trial monitoring 2 anchor the type-2-diabetes indication with reductions in any diabetes-related endpoint and all-cause mortality and a persistent macrovascular legacy effect. The Diabetes Prevention Program 3 and its long-term follow-up 456 support the diabetes-prevention rationale across 21 years. ADOPT 7 established glycemic durability of metformin monotherapy, and the Maruthur AHRQ comparative-effectiveness systematic review 35 integrated metformin into the broader oral and injectable antihyperglycemic landscape and supported its first-line position 12. The pharmacokinetic, mechanistic, and microbiome evidence base provides a coherent molecular explanation for the clinical effect 201725. The safety evidence frames the lactic-acidosis, B12, and cardiovascular risks at clinically actionable resolution 193324.
Off-label evidence is heterogeneous 30. For PCOS 8910 and gestational diabetes 11, randomized evidence is strong enough to support clinical use but does not extend to FDA labeling in the U.S. For cancer-incidence reduction 1516, evidence is observational, subject to immortal-time and indication bias, and not actionable. For aging biology and healthspan endpoints, evidence is hypothesis-generating; the TAME trial program is the appropriate test bed, and no phase III aging-endpoint trial has yet reported 26.
Evidence specifically supporting compounded preparations is absent, there is no parallel efficacy program for compounded metformin oral suspensions or capsules 362213. Compounded use is an extrapolation from the manufactured-product evidence base, justified case by case by documented patient-specific factors that the manufactured product cannot accommodate. Compounded preparations may differ from manufactured products in excipient profile, vehicle, concentration, and container closure; absorption and tolerability cannot be assumed equivalent without local data 301423.
Randomized controlled trial of intensive blood-glucose control with metformin vs sulfonylurea/insulin vs conventional dietary treatment in overweight adults with newly diagnosed type 2 diabetes
1704
Median 10.7 years
Metformin reduced any diabetes-related endpoint by 32%, diabetes-related death by 42%, and all-cause mortality by 36% vs conventional treatment; less weight gain and less hypoglycemia than sulfonylurea or insulin 1
Phase III, randomized, placebo-controlled trial of metformin 850 mg twice daily vs intensive lifestyle vs placebo in adults with impaired glucose tolerance
3234
Mean 2.8 years
Metformin reduced incident type 2 diabetes by 31% and lifestyle by 58% vs placebo 3
Long-term observational follow-up of the DPP cohort
2766
10 years
Cumulative incidence of diabetes remained lower in the metformin and lifestyle arms; risk reduction relative to placebo was 18% (metformin) and 34% (lifestyle) at 10 years 4
Pre-specified long-term weight-loss analysis of DPPOS participants
2776
15 years
Adherent metformin participants sustained mean ~2.0% weight reduction at 15 years; weight loss was greater with higher baseline fasting glucose and BMI 5
Twenty-one-year long-term effects and effect-heterogeneity analysis of the DPP/DPPOS cohort
—
21 years
Continued separation in cumulative diabetes incidence with effect heterogeneity by baseline BMI and fasting glucose; durable benefit for both metformin and lifestyle vs placebo 6
Randomized double-blind active-comparator trial of rosiglitazone, metformin, or glyburide monotherapy in newly diagnosed type 2 diabetes
4360
Median 4.0 years
Cumulative incidence of monotherapy failure was 15% with rosiglitazone, 21% with metformin, and 34% with glyburide; metformin durable and superior to glyburide 7
Randomized double-blind multi-arm trial of clomiphene, metformin, or both for infertility in PCOS
626
Up to 6 months
Live-birth rates: 22.5% clomiphene, 7.2% metformin, 26.8% combination; clomiphene superior to metformin and not significantly improved by metformin addition 9
Systematic review and meta-analysis of insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for PCOS-related oligo-amenorrhoea and subfertility
—
—
Metformin improves ovulation and pregnancy rates vs placebo but is inferior to clomiphene for live-birth endpoints 10
Systematic review of 347 comparative trials and cohort studies for fatal and nonfatal lactic acidosis with metformin in type 2 diabetes
70,490 patient-years on metformin
—
No cases of fatal or nonfatal lactic acidosis attributable to metformin; pooled upper confidence limit 4.3 cases per 100,000 patient-years, indistinguishable from non-metformin therapy 12
Long-term analysis of DPPOS participants for biochemical and clinical vitamin B12 deficiency
—
Up to ~13 years on metformin
Increased prevalence of biochemical (B12 <298 pg/mL) and clinical B12 deficiency with long-term metformin use vs placebo, with risk increasing as cumulative metformin exposure rises 13
Observational cohort comparing all-cause mortality of adults with type 2 diabetes initiated on metformin or sulfonylurea monotherapy with matched non-diabetic controls
Approximately 78,000 metformin initiators, 12,000 sulfonylurea initiators, and matched non-diabetic controls
—
Adults with type 2 diabetes initiated on metformin had lower all-cause mortality than matched non-diabetic controls; sulfonylurea initiators had higher mortality, hypothesis-generating signal motivating geroscience research 14
Systematic review of metformin use in patients with type 2 diabetes and chronic kidney disease
—
—
Available evidence supported safer metformin use at lower eGFR than the historical serum-creatinine-based cut-off; informed the 2016 FDA label revision to eGFR-based thresholds 22
Preclinical mechanistic study using rodent hepatocytes and in vivo models
—
—
Metformin suppresses gluconeogenesis through redox-mediated inhibition of mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH), independent of AMPK in this pathway 18
Comprehensive review of metformin clinical pharmacokinetics
—
—
Bioavailability ~50, 60%, renal excretion of unchanged drug as the dominant elimination pathway, plasma half-life 4, 9 hours, OCT1/OCT2/MATE-mediated transport 20
Randomized placebo-controlled trial with shotgun metagenomic and metabolomic analysis in treatment-naive adults with type 2 diabetes
—
—
Metformin produces reproducible shifts in microbial taxa (Escherichia, Akkermansia muciniphila) and short-chain fatty acid production that parallel glycemic response and contribute to therapeutic effect 17
Randomized controlled trial of metformin vs placebo with skeletal muscle and subcutaneous adipose biopsies in older adults
—
—
Metformin regulates parallel metabolic and non-metabolic pathways in skeletal muscle and adipose tissue, with effects on mitochondrial respiration and insulin signaling 23
Design and rationale paper for the TAME (Targeting Aging with Metformin) trial program
—
—
Frames metformin as a candidate intervention for composite biological-aging endpoints (CV events, cancer, dementia, mortality) in adults aged 65, 79 without diabetes; results not yet reported 25
Record-linkage observational cohort in Tayside, Scotland
—
—
23% reduction in incident cancer among adults with type 2 diabetes on metformin vs non-metformin antihyperglycemic therapy; hypothesis-generating, subject to immortal-time and time-related confounding 15
UK General Practice Research Database observational cohort
—
—
Differential cancer-incidence signals across glucose-lowering therapies; directionally favorable signal for metformin vs insulin 16. Subject to confounding-by-indication.
Systematic review and network meta-analysis of monotherapy and metformin-based combination therapy for type 2 diabetes
—
—
Integrated metformin into the broader oral and injectable antihyperglycemic landscape; supported metformin as first-line monotherapy on the basis of glycemic efficacy, weight, and safety profile 35
Mechanism detail
Detailed Mechanism of Compounded Metformin
Metformin is a small (165 Da) hydrophilic cationic molecule. It enters hepatocytes principally through organic cation transporter 1 (OCT1, SLC22A1) and accumulates in mitochondria along the electrochemical gradient. Within mitochondria it produces a mild, reversible inhibition of respiratory chain complex I, which lowers the ATP:ADP ratio, raises cytosolic AMP, and activates AMP-activated protein kinase (AMPK). AMPK activation suppresses transcription of gluconeogenic enzymes (PEPCK, G6Pase) and inhibits SREBP-1c-driven lipogenesis 19.
Madiraju and colleagues 18 identified mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH) as a non-AMPK-dependent molecular target of metformin. mGPDH inhibition raises cytosolic NADH and lowers the conversion of glycerol-3-phosphate to dihydroxyacetone phosphate, thereby suppressing glycerol-driven gluconeogenesis. This redox-based mechanism reconciles earlier observations that metformin can suppress gluconeogenesis at clinically relevant doses without sufficient AMPK activation in hepatocytes 19.
Microbiome-mediated mechanisms add a third layer. Wu and colleagues 17 performed shotgun metagenomic and metabolomic analyses of treatment-naive adults with type 2 diabetes randomized to metformin vs placebo and demonstrated reproducible shifts in microbial taxa (notably Escherichia and Akkermansia muciniphila) and short-chain fatty acid production that paralleled glycemic response. Metformin's high gut concentrations relative to plasma support direct microbiome activity as a clinically meaningful component of its effect.
In skeletal muscle and adipose tissue, metformin produces transcriptomic and proteomic changes consistent with improved fuel handling. Kulkarni and colleagues 23 characterized parallel metabolic and non-metabolic pathway regulation in older adults' skeletal muscle and subcutaneous adipose tissue, with effects on mitochondrial respiration and insulin signaling. Konopka and colleagues 24, however, demonstrated that metformin attenuates the mitochondrial adaptations to aerobic exercise training in older adults, a clinically relevant observation when metformin is used in combination with exercise-based interventions, including for prediabetes.
Metformin is a small hydrophilic cationic molecule (165 Da). Oral bioavailability of the immediate-release tablet is 50, 60% under fasting conditions and is reduced by ~25% with food in some studies; the extended-release formulation has comparable systemic exposure with a flatter Cmax profile. Plasma half-life is 4, 9 hours. Metformin is not metabolized; it is eliminated as unchanged drug in the urine, principally by tubular secretion via the renal organic cation transporters OCT2 and MATE1/MATE2-K, with glomerular filtration as a secondary route 2027.
Hepatocellular uptake is mediated by OCT1 (SLC22A1); intracellular accumulation in mitochondria along the membrane potential drives the mechanistic effects on complex I and mGPDH 181927. Genetic variation in OCT1 influences hepatic exposure and glycemic response, though clinically actionable pharmacogenetic testing is not in routine use.
Compounded oral suspensions and capsules may differ from the manufactured products in absorption rate, peak concentration, and food effect, particularly when vehicle viscosity, particle size, or excipient composition differs from the reference 28. The PK data summarized above are generated with manufactured Glucophage, Glucophage XR, and Riomet products and should not be assumed to translate to compounded preparations without local stability and absorption data.
Pharmacodynamics
Pharmacodynamic effects include reduction of fasting plasma glucose and post-prandial glucose, primarily through suppression of hepatic gluconeogenesis with secondary improvement in peripheral insulin sensitivity. HbA1c reduction is typically 1.0, 1.5% from baseline in adults with type 2 diabetes at therapeutic doses (1,500, 2,000 mg/day) 13. Weight is neutral to modestly favorable; sustained ~2% weight reduction is documented in long-term DPPOS analyses 5. Effects on lipids are modest (small decreases in LDL-C and triglycerides). The Wu microbiome work 17 documents reproducible gut-microbiome shifts and short-chain fatty acid changes that parallel glycemic response.
Comparative formulations
Comparing Compounded Metformin Formulations
The manufactured U.S. products are Glucophage (immediate-release tablet, 500/850/1000 mg), Glucophage XR / Glumetza / Fortamet (extended-release tablets, 500/750/1000 mg with formulation-specific release profiles), and Riomet (oral solution 100 mg/mL) 2728. Generic immediate-release and extended-release tablets are widely available. The drug substance is identical across products; differences are formulation-level (release rate, vehicle, container closure, excipient profile).
Compounded oral suspensions and capsules vary in vehicle, flavor, excipient profile, and concentration. They are not bioequivalent to the manufactured products; clinicians should anticipate that local absorption and tolerability may differ from manufactured-product published data, particularly when switching between commercial Riomet and a compounded suspension or between a commercial tablet and a custom-strength capsule.
Storage
Compounded Metformin Storage and Handling
Manufactured Glucophage, Glucophage XR, Glumetza, and Fortamet tablets are stored at controlled room temperature (20, 25°C, with excursions permitted to 15, 30°C) in a tightly closed container, protected from moisture 27. Riomet oral solution is stored at controlled room temperature in the original container 28.
Compounded oral suspensions and capsules are stored per the pharmacy's stability data and beyond-use-date assignment under USP <795>. Suspensions are typically refrigerated to preserve flavor and chemical stability; capsules at controlled room temperature 32.
RonanRx operations
Compounded Metformin Compounding & Operations
503A compounding
Compounded metformin is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares nonsterile oral suspensions and capsules per USP General Chapter <795>, the official compendial standard for nonsterile pharmaceutical compounding, with documented active ingredient sourcing, gravimetric verification, content-uniformity assessment for capsule batches, and full lot traceability 3132. Suspension stability is assigned per pharmacy-validated stability data or referenced compendial data.
Beyond-use dating, ingredient identity verification, and stability assessment follow USP <795> requirements. Each compounded batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing.
Pharmacist review
Each prescription for compounded metformin undergoes pharmacist review prior to dispensing 22. The review confirms: a documented patient-specific clinical reason that the manufactured Glucophage, Glucophage XR, Glumetza, Fortamet, or Riomet product is not appropriate (documented excipient sensitivity, need for a vehicle or flavor that commercial Riomet does not provide, custom low-strength capsule for renal-impaired patients in the eGFR 30, 45 band, or an active shortage of a specific presentation); current eGFR and the absence of contraindications including eGFR <30 mL/min/1.73 m², decompensated heart failure, or hepatic impairment 27; appropriate concomitant medication review including hypoglycemia risk if combined with insulin or sulfonylureas, and renal cation-transporter interactions; and a prescribed regimen consistent with FDA-label titration unless the prescriber documents a patient-specific reason.
RonanRx does not fill prescriptions that read as routine substitution of compounded for manufactured product without documented clinical rationale, consistent with FDA guidance on compounded copies of commercially available drugs 30. Because Riomet oral solution and a wide range of tablet strengths are commercially available, the bar for a documented patient-specific need is meaningful and the routine cases at other compounds (e.g., adult preference for a sweetened liquid where Riomet is acceptable) do not qualify 28.
Quality and traceability
Active pharmaceutical ingredients are sourced from FDA-registered facilities with documented certificates of analysis. Each batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, content-uniformity result (for capsules), and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements.
Cold chain
Compounded metformin oral suspensions are typically refrigerated to preserve flavor and chemical stability; capsules are stored at controlled room temperature 28. Manufactured Glucophage, Glucophage XR, Glumetza, Fortamet, and Riomet are room-temperature products and do not require a cold chain in transit 27. Patients receiving a refrigerated suspension are educated on refrigeration on arrival and inspection for temperature excursions.
FAQ
Frequently Asked Questions About Compounded Metformin
Is compounded metformin the same as Glucophage or Riomet?
No. Glucophage, Glucophage XR, Glumetza, Fortamet, and Riomet are the FDA-approved manufactured metformin products 2728. Compounded metformin is pharmacy-prepared on a patient-specific prescription and is not bioequivalent to the manufactured products. Compounded drugs are not FDA-approved31.
Why would anyone compound metformin when Glucophage and Riomet are widely available?
The 503A role is narrow and patient-specific. Reasons that qualify include: documented sensitivity to an excipient in the manufactured tablet or commercial Riomet; need for a flavor or vehicle that commercial Riomet does not provide for a pediatric or dysphagia patient; or a custom low-strength capsule for renal-impaired patients (eGFR 30, 45) titrated below the lowest commercial tablet 28. Cost or general preference does not qualify under FDA's essentially-a-copy guidance 273022.
What does the diabetes-prevention evidence say?
The Diabetes Prevention Program randomized 3,234 adults with impaired glucose tolerance and reported a 31% reduction in incident type 2 diabetes with metformin and a 58% reduction with intensive lifestyle vs placebo over a mean 2.8 years 356. Long-term follow-up at 10, 15, and 21 years continues to show separation in cumulative diabetes incidence with metformin 4. ADA Standards of Care recommend metformin for diabetes prevention in selected adults with prediabetes, but this is off-label in the United States.
How serious is the lactic acidosis warning?
Metformin labeling carries a Boxed Warning for lactic acidosis, inherited from the phenformin era. The Cochrane systematic review by Salpeter and colleagues pooled 347 trials and 70,490 patient-years on metformin and found no cases of lactic acidosis attributable to metformin; the pooled upper confidence limit was 4.3 cases per 100,000 patient-years, indistinguishable from non-metformin therapy 122227. Risk is concentrated in patients with severe renal impairment, decompensated heart failure, or acute illness with reduced perfusion.
Does long-term metformin cause vitamin B12 deficiency?
Aroda and colleagues analyzed DPPOS participants on long-term metformin and reported increased prevalence of biochemical and clinical vitamin B12 deficiency vs placebo, with risk rising as cumulative metformin exposure increased 13. Annual or biennial serum B12 monitoring is appropriate for patients on multi-year metformin therapy, especially older adults and those with neuropathy symptoms.
What is the role of metformin in PCOS and gestational diabetes?
For PCOS, randomized evidence positions metformin as a metabolic adjunct rather than a first-line ovulation-induction agent (clomiphene is superior on live-birth endpoints; letrozole is the current preferred first-line) 9. For gestational diabetes, the MIG trial demonstrated non-inferiority of metformin vs insulin on a composite perinatal outcome; obstetric society positioning varies internationally 81011. Both uses are off-label in the U.S.
Can metformin slow aging?
The TAME (Targeting Aging with Metformin) trial program positions metformin as a candidate intervention for composite biological-aging endpoints in adults aged 65, 79 without diabetes 26. Justification rests on the favorable safety profile, mechanistic plausibility, and observational signals such as the Bannister cohort (where adults with type 2 diabetes on metformin had lower all-cause mortality than matched non-diabetic controls) 14. No phase III aging-endpoint trial of metformin has yet reported, so a clinical claim is not currently supported 25.
Who should not take metformin?
Contraindicated at eGFR <30 mL/min/1.73 m², in acute or chronic metabolic acidosis (including diabetic ketoacidosis), and in known hypersensitivity. Initiation is not recommended at eGFR 30, 45. Hold metformin during acute illness that may impair renal function and before iodinated contrast procedures per labeling 2722.
Does RonanRx sell compounded metformin directly to patients?
No. Compounded metformin requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that the manufactured Glucophage, Glucophage XR, Glumetza, Fortamet, or Riomet product is not appropriate, plus pharmacist review before dispensing 30. RonanRx is not a direct-to-consumer storefront 31.
Clinician resource
Download the Compounded Metformin Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[ukpds34_1998] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. Lancet. 1998. PMID 9742977. (accessed 2026-05-11)
[holman2008] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes.. New England Journal of Medicine. 2008. PMID 18784090. (accessed 2026-05-11)
[knowler2002] Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.. New England Journal of Medicine. 2002. PMID 11832527. (accessed 2026-05-11)
[knowler2009] Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.. Lancet. 2009. PMID 19878986. (accessed 2026-05-11)
[aroda2019] Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM; Diabetes Prevention Program Research Group. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.. Annals of Internal Medicine. 2019. PMID 31009939. (accessed 2026-05-11)
[dpp2025] Diabetes Prevention Program Research Group. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial.. Lancet Diabetes and Endocrinology. 2025. PMID 40311647. (accessed 2026-05-11)
[kahn2006] Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.. New England Journal of Medicine. 2006. PMID 17145742. (accessed 2026-05-11)
[moll2006] Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.. BMJ. 2006. PMID 16769748. (accessed 2026-05-11)
[legro2007] Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.. New England Journal of Medicine. 2007. PMID 17287476. (accessed 2026-05-11)
[tang2012] Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.. Cochrane Database of Systematic Reviews. 2012. PMID 22592687. (accessed 2026-05-11)
[rowan2008] Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes.. New England Journal of Medicine. 2008. PMID 18463376. (accessed 2026-05-11)
[salpeter2010] Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.. Cochrane Database of Systematic Reviews. 2010. PMID 20393934. (accessed 2026-05-11)
[aroda_b12_2016] Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.. Journal of Clinical Endocrinology and Metabolism. 2016. PMID 26900641. (accessed 2026-05-11)
[bannister2014] Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.. Diabetes, Obesity and Metabolism. 2014. PMID 25041462. (accessed 2026-05-11)
[evans2005] Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients.. BMJ. 2005. PMID 15849206. (accessed 2026-05-11)
[currie2009] Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.. Diabetologia. 2009. PMID 19572116. (accessed 2026-05-11)
[wu2017] Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.. Nature Medicine. 2017. PMID 28530702. (accessed 2026-05-11)
[foretz2014] Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Control of gluconeogenesis by metformin: does redox trump energy charge?. Cell Metabolism. 2014. PMID 25100057. (accessed 2026-05-11)
[graham2011] Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin.. Clinical Pharmacokinetics. 2011. PMID 21241070. (accessed 2026-05-11)
[inzucchi2014] Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review.. JAMA. 2014. PMID 25536258. (accessed 2026-05-11)
[kulkarni2018] Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, Mar JC, Hawkins M, Crandall JP, Barzilai N. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults.. Aging Cell. 2018. PMID 29383869. (accessed 2026-05-11)
[konopka2019] Konopka AR, Laurin JL, Schoenberg HM, Reid JJ, Castor WM, Wolff CA, Musci RV, Safairad OD, Linden MA, Biela LM, Bailey SM, Hamilton KL, Miller BF. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults.. Aging Cell. 2019. PMID 30548390. (accessed 2026-05-11)
[justice2018] Justice JN, Niedernhofer L, Robbins PD, Aroda VR, Espeland MA, Kritchevsky SB, Kuchel GA, Barzilai N. Development of Clinical Trials to Extend Healthy Lifespan.. Cardiovascular Endocrinology and Metabolism. 2018. PMID 30906924. (accessed 2026-05-11)
[justice2022] Justice JN, Leng XI, Verghese J, Glynn NW, Hsu FC, Adkins KS, Bertrand AC, Bray MS, Brown PJ, Carrico AW, Espeland MA, Hicks GE, Klepin HD, Lin RC, Lopez OL, Newman AB, Pahor M, Volpi E, Houston DK, Reidler JS, Kirkland JL, Kritchevsky SB, Kuchel GA. Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization.. Aging Cell. 2022. PMID 35343051. (accessed 2026-05-11)
[fda_shortage_list] U.S. Food and Drug Administration. FDA Drug Shortages Database — Metformin Hydrochloride Extended-Release Tablets (intermittent listings, including 2020 nitrosamine-related recalls). FDA Drug Shortages. 2024. https://www.accessdata.fda.gov/scripts/drugshortages/ (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
[rena2017] Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.. Diabetologia. 2017. PMID 28776086. (accessed 2026-05-11)
[roussel2010] Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis.. Archives of Internal Medicine. 2010. PMID 21098347. (accessed 2026-05-11)
[maruthur2016] Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.. Annals of Internal Medicine. 2016. PMID 27088241. (accessed 2026-05-11)
[salpeter2006_lacticacidosis] Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.. Cochrane Database of Systematic Reviews. 2006. PMID 16437448. (accessed 2026-05-11)
How to access
How to Access Compounded Metformin
Compounded Compounded Metformin is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Compounded Metformin, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Compounded Metformin.
